Patrick Trojer, Triana Biomedicines CEO
October 15, 2024 08:01 AM EDTUpdated 08:24 AM
Deals
R&D

Pfiz­er part­ners with mol­e­c­u­lar glue start­up Tri­ana in $49M up­front deal

Ryan Cross

Senior Science Correspondent

Pfiz­er is deep­en­ing its in­vest­ment in pro­tein de­graders through a new part­ner­ship with Tri­ana Bio­med­i­cines, a start­up work­ing in the trendy field of mol­e­c­u­lar glues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times